There were just three listings for Woodcock between January 1999 and December 2006, even though she occupied two positions during that time that required her meetings to be listed: director of the center for drug evaluation and research and, later, deputy commissioner for operations. Investigators found no listings for Galson, who took over the drugs office from Woodcock on a full-time basis in July 2005.Yeah, that's pretty blank. I'm not suggesting it is entirely wrong for them to have met with drug industry officials, as that is obviously part of the job. But why cover it up? At the very least, it creates an impression that there is something to hide. Worry not, the FDA has described it as "administrative oversight." Perhaps the FDA has an intern in charge of schedules who resembles the PhRMA intern of John Mack fame.
Hat Tip: AHRP